MA54521A - Dérivés d'oxopyridine substitués - Google Patents

Dérivés d'oxopyridine substitués

Info

Publication number
MA54521A
MA54521A MA054521A MA54521A MA54521A MA 54521 A MA54521 A MA 54521A MA 054521 A MA054521 A MA 054521A MA 54521 A MA54521 A MA 54521A MA 54521 A MA54521 A MA 54521A
Authority
MA
Morocco
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
oxopyridine
Prior art date
Application number
MA054521A
Other languages
English (en)
Inventor
Sonja Anlauf
Pascal Ellerbrock
Sebastian Essig
Kersten Matthias Gericke
Stefan Heitmeier
Alexander Hillisch
Dieter Lang
Katharina Meier
Xianghai Meng
Thomas Neubauer
Susanne Röhrig
Martina Schäfer
Jan Stampfuss
Adrian Tersteegen
Hongping Wang
Zengqiang Zou
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA54521A publication Critical patent/MA54521A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054521A 2018-12-21 2019-12-18 Dérivés d'oxopyridine substitués MA54521A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21

Publications (1)

Publication Number Publication Date
MA54521A true MA54521A (fr) 2022-03-30

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054521A MA54521A (fr) 2018-12-21 2019-12-18 Dérivés d'oxopyridine substitués

Country Status (22)

Country Link
EP (1) EP3898633A1 (fr)
JP (1) JP2022514303A (fr)
KR (1) KR20210106504A (fr)
CN (1) CN113474348A (fr)
AR (1) AR117435A1 (fr)
AU (1) AU2019407909B2 (fr)
BR (1) BR112021009435A2 (fr)
CA (1) CA3124220A1 (fr)
CL (1) CL2021001613A1 (fr)
CO (1) CO2021007908A2 (fr)
CR (1) CR20210342A (fr)
DO (1) DOP2021000128A (fr)
EA (1) EA202191764A1 (fr)
EC (1) ECSP21043895A (fr)
IL (1) IL283990A (fr)
JO (1) JOP20210161A1 (fr)
MA (1) MA54521A (fr)
MX (1) MX2021007508A (fr)
PE (1) PE20211790A1 (fr)
SG (1) SG11202104384PA (fr)
TW (1) TW202039510A (fr)
WO (1) WO2020127504A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63338B1 (sr) * 2018-03-15 2022-07-29 Bayer Ag Proces pripreme dva derivata 4-{[(2s)-2-{4-[5-hloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
MX2023010614A (es) 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
MX2023010629A (es) 2021-03-09 2023-09-19 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida.
WO2022189280A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
WO2024223790A1 (fr) * 2023-04-28 2024-10-31 Basf Se Utilisation de 4-alcoxypentanoates d'alkyle comme arômes chimiques
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
WO2008079787A2 (fr) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Activateurs de glucokinase
WO2014160592A2 (fr) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (fr) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substituée
EP3197896B1 (fr) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
EP3197872B1 (fr) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridines en tant qu'inhibiteurs du facteur xia pour le traitement de maladies thrombotiques
EP3197889B1 (fr) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
ES2712886T3 (es) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EP3197880B1 (fr) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués à effet anti-inflammatoire et anti-thrombotique
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
CA2979937A1 (fr) * 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Derives d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (fr) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués

Also Published As

Publication number Publication date
CN113474348A (zh) 2021-10-01
SG11202104384PA (en) 2021-05-28
AR117435A1 (es) 2021-08-04
PE20211790A1 (es) 2021-09-09
JOP20210161A1 (ar) 2023-01-30
EA202191764A1 (ru) 2021-10-22
AU2019407909A1 (en) 2021-05-27
ECSP21043895A (es) 2021-07-30
CO2021007908A2 (es) 2021-07-19
KR20210106504A (ko) 2021-08-30
AU2019407909B2 (en) 2023-05-25
JP2022514303A (ja) 2022-02-10
DOP2021000128A (es) 2021-09-30
WO2020127504A1 (fr) 2020-06-25
TW202039510A (zh) 2020-11-01
CA3124220A1 (fr) 2020-06-25
CL2021001613A1 (es) 2021-12-03
CR20210342A (es) 2021-08-09
BR112021009435A2 (pt) 2021-08-17
IL283990A (en) 2021-07-29
EP3898633A1 (fr) 2021-10-27
MX2021007508A (es) 2021-08-05

Similar Documents

Publication Publication Date Title
IL283197A (en) Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
PT3958977T (pt) Derivados de camptotecina
MA54521A (fr) Dérivés d'oxopyridine substitués
HUE071131T2 (hu) Helyettesített 1,2-dihidro-3H-pirazolo[3,4-d]pirimidin-3-on-származékok
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3768669T3 (da) Piperazinazaspiroderivater
EP4037676A4 (fr) Dérivés cannabinoïdes
EP3997095A4 (fr) Dérivés cannabinoïdes
EP3999490A4 (fr) Dérivés cannabinoïdes
EP4077334C0 (fr) Dérivés furoindazole
MA49127A (fr) Dérivés d'indole n-substitués
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
EP3808747A4 (fr) Composé d'imidazopyridinone
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3762456A4 (fr) Composition de dispersant d'asphaltène
PT3796975T (pt) Derivados de sulfonilaminobenzamida
MA56504A (fr) Dérivés de pyridin-3-yle
MA49704A (fr) Dérivés d'acide biliaire à marquage isotopique
DK3894410T3 (da) Substituerede xanthinderivater